Twist Bioscience (NASDAQ:TWST) Research Coverage Started at Wolfe Research

Wolfe Research began coverage on shares of Twist Bioscience (NASDAQ:TWST) in a research report sent to investors on Friday, Marketbeat.com reports. The firm issued an outperform rating and a $60.00 price target on the stock.

Other analysts have also issued research reports about the company. Scotiabank upped their price objective on Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, November 19th. Barclays cut their price target on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a report on Tuesday, November 19th. Robert W. Baird boosted their price objective on Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 19th. Leerink Partners raised their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. Finally, Evercore ISI boosted their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, Twist Bioscience presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.90.

Twist Bioscience Stock Performance

NASDAQ TWST opened at $47.50 on Friday. Twist Bioscience has a one year low of $27.41 and a one year high of $60.90. The firm has a 50 day simple moving average of $44.94 and a 200-day simple moving average of $46.70. The firm has a market cap of $2.82 billion, a price-to-earnings ratio of -13.19 and a beta of 1.82.

Insiders Place Their Bets

In other Twist Bioscience news, SVP Paula Green sold 3,310 shares of the business’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $43.21, for a total value of $143,025.10. Following the completion of the sale, the senior vice president now owns 84,585 shares in the company, valued at approximately $3,654,917.85. The trade was a 3.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Emily M. Leproust sold 14,334 shares of the stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total value of $639,296.40. Following the completion of the sale, the chief executive officer now directly owns 589,552 shares of the company’s stock, valued at $26,294,019.20. The trade was a 2.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 101,787 shares of company stock valued at $4,584,508. 3.92% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Twist Bioscience

A number of institutional investors have recently modified their holdings of TWST. State Street Corp grew its position in Twist Bioscience by 19.9% during the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after purchasing an additional 526,028 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Twist Bioscience by 1.9% in the third quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company’s stock valued at $61,807,000 after buying an additional 26,145 shares during the last quarter. Thrivent Financial for Lutherans acquired a new stake in shares of Twist Bioscience during the third quarter worth about $43,992,000. Wellington Management Group LLP grew its holdings in shares of Twist Bioscience by 188.5% during the third quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after buying an additional 521,272 shares during the last quarter. Finally, Fred Alger Management LLC increased its position in Twist Bioscience by 17.1% in the 3rd quarter. Fred Alger Management LLC now owns 767,149 shares of the company’s stock valued at $34,660,000 after acquiring an additional 112,272 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.